Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

DaVita Inc. (DVA) — XLV Health Care · S&P 500 Profile |達維塔公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

DaVita Inc. (DVA) — Business, History & S&P 500 Profile | 達維塔公司介紹

DaVita Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #480 · 達維塔公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 5, 2026
Financials: FY2025
MARKET CAP
$11.94B
Nov 5, 2026
S&P 500 WEIGHT
0.02%
Rank #480 · Nov 5, 2026
SECTOR RANK
#55
Health Care · Nov 5, 2026
S&P 500 RANK
#480
0.02% · Nov 5, 2026

SNAPSHOT

TickerDVA
CompanyDaVita Inc.
GICS sector / industryHealth Care (XLV) / Health Care Services
S&P 500 rank (by weight)#480 · 0.02% (Nov 5, 2026)
Sector rank#55 of 60 in Health Care (Nov 5, 2026)
HeadquartersDenver, Colorado, United States
Founded1979
CEOJavier J. Rodriguez (Chief Executive Officer)
Employees~78,000 (as of December 31, 2025)
Market cap$11.94B (Nov 5, 2026)
SEC filingsEDGAR — CIK 927066

WHAT IT DOES

DaVita Inc. is one of the largest kidney care companies in the United States. Its core U.S. dialysis business treats patients with chronic kidney failure and end-stage kidney disease (ESKD), who typically need dialysis three times a week unless they receive a transplant. At December 31, 2025 it operated 2,657 outpatient dialysis centers in the U.S. serving approximately 200,500 patients, provided inpatient dialysis services in hospitals, and ran related clinical laboratories; outside the U.S. it operated dialysis centers in 14 other countries serving about 94,500 patients, as described in its Form 10-K reporting. DaVita is paid mainly by health insurers rather than by patients directly. Government programs dominate volume — about 89% of its U.S. patients were covered by government-based insurance in 2025 and about 68% of U.S. dialysis patient service revenues came from Medicare and other government programs — while commercial insurers, covering a minority of patients, reimburse at much higher rates and generate nearly all of the profit. Around this core, its ancillary segment adds integrated kidney care, disease management, clinical research, physician services and transplant software, aiming to manage patients earlier in the course of kidney disease.

BUSINESS SEGMENTS

U.S. DialysisKidney dialysis services for patients with chronic kidney failure and end-stage kidney disease through 2,657 U.S. outpatient dialysis centers serving approximately 200,500 patients at December 31, 2025, plus inpatient dialysis in hospitals and related laboratory services. Total segment revenues were $11,792.9M in FY2025, including $61.0M of intersegment revenues.
Other — Ancillary ServicesAncillary and integrated kidney-care services, including international dialysis operations, integrated care and disease-management programs for kidney patients, clinical research, physician services and transplant-related software (MedSleuth). Total segment revenues were $1,922.3M in FY2025, including $11.2M of intersegment revenues.
Segment revenues include intersegment revenues; after eliminating $72.2M of intersegment revenues, segment revenues of $13,715.2M reconcile to consolidated revenues of $13,643.1M for FY2025.

HISTORY

YearMilestone
1979The business was founded as Medical Ambulatory Care, Inc., a subsidiary of National Medical Enterprises (now Tenet Healthcare), the origin DaVita traces its history to.
1994DLJ Merchant Banking Partners acquired 70% of the company in a $75.5 million leveraged buyout; it was renamed Total Renal Care Holdings, Inc. and went public in an October 1995 IPO.
1999After a difficult integration of Renal Treatment Centers, the CEO and CFO resigned and Kent J. Thiry became CEO in October 1999; the company was renamed DaVita Inc. in October 2000, a name derived from the Italian phrase for 'giving life'.
2005DaVita acquired Gambro Healthcare, greatly expanding its U.S. dialysis center network.
2019DaVita sold DaVita Medical Group — built around the $4.42 billion 2012 acquisition of HealthCare Partners — to UnitedHealth Group's Optum for $4.3 billion, refocusing the company on kidney care; Javier J. Rodriguez also became CEO in 2019.

COMPETITIVE POSITION

  • Fresenius Medical Care (FMS) — the other member of the U.S. dialysis duopoly and DaVita's principal global rival
  • U.S. Renal Care — large privately held U.S. dialysis provider competing for centers, physicians and patients
  • Satellite Healthcare — nonprofit U.S. dialysis provider, active in home dialysis and selected regional markets
  • Hospital-based and independent regional dialysis operators — smaller providers that compete center-by-center in local markets

FINANCIAL SNAPSHOT

Total revenue$13.64B (FY2025 revenue)
Operating income$2.04B (FY2025 operating income)
Net income$746.8M (FY2025 net income)
Diluted EPS$9.84 (FY2025 diluted EPS)
Source: DaVita Inc. fiscal 2025 Form 10-K (period ended December 31, 2025; filed February 11, 2026). Exact figures: total revenue $13,643.1M; operating income $2,043.6M; net income attributable to DaVita Inc. $746.8M (total net income including noncontrolling interests was $1,078.7M); diluted EPS attributable to DaVita Inc. $9.84. The company employed approximately 78,000 teammates as of December 31, 2025, about 72% of them in the U.S. Notable items: FY2025 U.S. dialysis results included charges related to a 2025 cybersecurity incident, and in 2025 about 68% of U.S. dialysis patient service revenues came from Medicare and other government-based health insurance programs.

KEY RISKS

  • Reimbursement risk: about 68% of FY2025 U.S. dialysis patient service revenues came from Medicare and other government programs, so U.S. rate-setting decisions directly drive margins
  • Payer-mix risk: profitability depends on a minority of commercially insured patients; shifts toward government coverage or narrower commercial networks would hurt earnings
  • Regulatory and legal exposure, including False Claims Act and anti-kickback enforcement, antitrust scrutiny of dialysis consolidation, and litigation history detailed in its filings
  • Clinical labour costs and shortages, plus operational and cybersecurity risk — FY2025 results already included charges tied to a 2025 cybersecurity incident

WHY IT MATTERS FOR THE S&P 500

DaVita is a small-weight Health Care constituent: rank #480 by weight at 0.02% as of Nov 5, 2026, and #55 in Health Care. Its weight understates its real-world footprint: it is one of only two large-scale operators in U.S. dialysis, a recurring, non-discretionary treatment market.

SOURCES & METHODOLOGY

Financials, segments, headquartersDaVita Inc. fiscal 2025 Form 10-K via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 5, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$11.94B (Slickcharts, Nov 5, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

DVA

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號DVA
公司DaVita Inc.(達維塔)
GICS 板塊/行業健康護理(XLV)/醫療護理服務
標普500排名(按權重)#480 · 0.02%(Nov 5, 2026)
板塊內排名健康護理板塊 #55(共 60 家)(Nov 5, 2026)
總部美國科羅拉多州丹佛
成立1979年
執行長Javier J. Rodriguez(行政總裁)
員工約 78,000 名(截至 2025 年 12 月 31 日)
市值$11.94B(Nov 5, 2026)
SEC 申報EDGAR — CIK 927066

業務概覽

DaVita Inc. 是美國最大的腎臟護理公司之一。其核心美國透析業務服務慢性腎衰竭及末期腎病(ESKD)患者,這類患者除非接受腎臟移植,通常需每週接受三次透析。截至 2025 年 12 月 31 日,公司在美國營運 2,657 間門診透析中心,服務約 200,500 名患者,並在醫院提供住院透析服務及營運相關臨床實驗室;在美國以外,根據其 Form 10-K 的披露,公司於另外 14 個國家營運透析中心,服務約 94,500 名患者。 DaVita 的收入主要來自醫療保險機構而非患者直接付款。政府計劃主導業務量——2025 年約 89% 的美國患者由政府醫療保險承保,約 68% 的美國透析患者服務收入來自 Medicare 及其他政府計劃——而商業保險機構雖只承保少數患者,但報銷率遠高於政府計劃,貢獻幾乎全部利潤。在此核心之外,其輔助服務分部提供綜合腎臟護理、疾病管理、臨床研究、醫生服務及移植軟件,旨在於腎病較早期階段管理患者。

業務板塊

美國透析業務透過 2,657 間美國門診透析中心為慢性腎衰竭及末期腎病患者提供腎臟透析服務,截至 2025 年 12 月 31 日服務約 200,500 名患者,另有醫院住院透析及相關實驗室服務。2025 財年分部總收入為 117.929 億美元,包括 0.610 億美元分部間收入。
其他——輔助服務輔助及綜合腎臟護理服務,包括國際透析業務、為腎病患者而設的綜合護理及疾病管理計劃、臨床研究、醫生服務及與移植相關的軟件(MedSleuth)。2025 財年分部總收入為 19.223 億美元,包括 0.112 億美元分部間收入。
分部收入包括分部間收入;扣除 0.722 億美元分部間收入後,137.152 億美元的分部收入與 2025 財年綜合收入 136.431 億美元對應。

歷史

年份里程碑
1979業務以 Medical Ambulatory Care, Inc. 之名創立,是 National Medical Enterprises(現稱 Tenet Healthcare)的附屬公司,DaVita 的歷史即源於此。
1994DLJ Merchant Banking Partners 以 7,550 萬美元槓桿收購公司 70% 股權;公司改名為 Total Renal Care Holdings, Inc.,並於 1995 年 10 月首次公開招股上市。
1999在 Renal Treatment Centers 的整合困難重重後,行政總裁及財務總裁辭職,Kent J. Thiry 於 1999 年 10 月出任行政總裁;公司於 2000 年 10 月改名為 DaVita Inc.,名字源自意大利語「賦予生命」之意。
2005DaVita 收購 Gambro Healthcare,大幅擴展其美國透析中心網絡。
2019DaVita 以 43 億美元將 DaVita Medical Group(源於 2012 年以 44.2 億美元收購的 HealthCare Partners)出售予 UnitedHealth Group 旗下的 Optum,令公司重新聚焦腎臟護理;Javier J. Rodriguez 亦於 2019 年出任行政總裁。

競爭地位

  • Fresenius Medical Care(FMS)——美國透析市場雙頭壟斷的另一成員,亦是 DaVita 的主要全球競爭對手
  • U.S. Renal Care——大型私人持有的美國透析服務商,爭奪中心、醫生及患者
  • Satellite Healthcare——非牟利美國透析服務商,活躍於居家透析及部分地區市場
  • 醫院旗下及獨立地區透析營運商——在本地市場逐間中心競爭的較小型服務商

財務快照

總收入136.43 億美元(2025 財年收入)
營業利潤20.44 億美元(2025 財年營業利潤)
淨利潤7.47 億美元(2025 財年淨利潤)
稀釋 EPS9.84 美元(2025 財年稀釋 EPS)
資料來源:DaVita Inc. 2025 財年 Form 10-K(期間截至 2025 年 12 月 31 日;於 2026 年 2 月 11 日提交)。確切數字:總收入 136.431 億美元;營業收入 20.436 億美元;歸屬於 DaVita Inc. 的淨收入 7.468 億美元(包括非控股權益的淨收入總額為 10.787 億美元);歸屬於 DaVita Inc. 的稀釋每股盈利 9.84 美元。截至 2025 年 12 月 31 日,公司僱用約 78,000 名員工,當中約 72% 位於美國。值得注意項目:2025 財年美國透析業績包括與 2025 年一宗網絡安全事件相關的支出,而 2025 年約 68% 的美國透析患者服務收入來自 Medicare 及其他政府醫療保險計劃。

主要風險

  • 報銷風險:2025 財年約 68% 的美國透析患者服務收入來自 Medicare 及其他政府計劃,因此美國的費率決定直接影響利潤率
  • 付款方組合風險:盈利依賴少數由商業保險承保的患者;若轉向政府承保或商業網絡收窄,盈利將受損
  • 監管及法律風險,包括《虛假申報法》及反回扣法規的執法、對透析市場整合的反壟斷審查,以及其申報文件詳載的訴訟歷史
  • 臨床人力成本及人手短缺,加上營運及網絡安全風險——2025 財年業績已包括與 2025 年一宗網絡安全事件相關的支出

對標普500的重要性

DaVita 是權重較小的健康護理成分股:截至 2026 年 11 月 5 日,按權重排名第 480 位,權重為 0.02%,在健康護理板塊中排名第 55 位。其權重低估了它的實際影響力:它是美國透析市場僅有的兩家大型營運商之一,而透析是具經常性、非可選性的治療市場。

來源與方法

財務、板塊、總部DaVita Inc. 2025 財年 Form 10-K(經 SEC EDGAR,見財務摘要附註);總部、行政總裁及歷史資料來自 Form 10-K 及 Wikipedia 公司簡介
指數權重與排名Slickcharts 標普 500 權重,Nov 5, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$11.94B(Slickcharts,Nov 5, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

DVA

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · DVA
Data as of Nov 5, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Align Technology, Inc. (ALGN) — XLV Health Care · S&P 500 Profile |愛齊科技公司介紹Next · UDR, Inc. (UDR) — XLRE Real Estate · S&P 500 Profile |UDR, Inc.公司介紹

Entered 2026-11-04 14:39 · updated 2026-11-14 23:20 · rev 7